Europe’s common data conundrum

The benefits of deploying a common data model for pharmacovigilance surveillance and postmarket studies are clear, but an EMA workshop held in December to discuss different models highlighted challenges to implementation.

Topping the list are sources of sustainable funding and compliance with the EU’s strict privacy laws...